JPRN-UMIN000021560已完成未知
A study to evaluate the relation between the efficacy and early Immune Related Advers Events of Nivolmab in patients with non-small cell lung cancer - A study to evaluate the relation between the efficacy and early Immune Related Advers Events of Nivolmab in patients with non-small cell lung cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 43
研究概览
简要总结
Patients with irAEs were associated with a significantly longer median progression-free survival than those without. These findings were comparable to those for patients with and without irAEs 6 weeks after commencement of nivolumab treatment.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Subjects with autoimmune disease. 2)Subjects with interstitial lung disease. 3)Receiving continuous systemic corticosteroid. 4)Prior therapy with antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. 5)Dementia or psychological disorder difficult to participate in this clinical study. 6)Uncontrolled intercurrent illness including symptomatic cardiac arrhythmia, or diabetes, Intestinal obstruction.
研究者
相似试验
终止
3 期
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLCNon Small Cell Lung CarcinomaNCT00234468AstraZeneca490
已完成
不适用
Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory FailureAcute Respiratory FailureNCT01707303Wake Forest University100
已完成
不适用
ECP for Immune-related Adverse Events After Checkpoint Inhibitor TreatmentImmune Related Adverse EventsHepatitisColitisDermatitisNCT05414552University of Freiburg11
已完成
不适用
A randomised study about the effect on survival of hormonal therapy versus hormonal therapy plus local external radiation therapy in patients with primary diagnosed metastasised (M+) prostate cancer.Prostate cancerNL-OMON29395Onze Lieve Vrouwe Gasthuis, afdeling urologie, Amsterdam. Erasmus Medisch Centrum, afdeling urologie Rotterdam (P.C.M.S. Verhagen)446
已完成
2 期
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder CancerUrologic NeoplasmsMetastatic Bladder CancerUrinary Tract NeoplasmsNCT01454089Achieve Life Sciences183